KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBIT (2016 - 2025)

Historic EBIT for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $28.4 million.

  • Rigel Pharmaceuticals' EBIT rose 10219.12% to $28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 115172.05%. This contributed to the annual value of $24.2 million for FY2024, which is 21806.16% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its EBIT stood at $28.4 million for Q3 2025, which was up 10219.12% from $61.1 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year EBIT high stood at $61.1 million for Q2 2025, and its period low was -$26.3 million during Q1 2022.
  • Moreover, its 5-year median value for EBIT was -$4.5 million (2023), whereas its average is $2.0 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 16289.31% in 2022, then skyrocketed by 1356957.49% in 2025.
  • Rigel Pharmaceuticals' EBIT (Quarter) stood at -$21.4 million in 2021, then surged by 109.71% to $2.1 million in 2022, then fell by 5.44% to $2.0 million in 2023, then soared by 747.15% to $16.7 million in 2024, then soared by 70.64% to $28.4 million in 2025.
  • Its last three reported values are $28.4 million in Q3 2025, $61.1 million for Q2 2025, and $12.8 million during Q1 2025.